2-methyl-N-pyridin-4-yl-acrylamide | 40000-72-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-methyl-N-pyridin-4-yl-acrylamide
• 英文别名: 2-methyl-N-pyridin-4-ylacrylamide；2-methyl-N-pyridin-4-ylprop-2-enamide
• CAS: 40000-72-4
• 化学式: C₉H₁₀N₂O
• mdl: MFCD03086075
• 分子量: 162.191
• InChiKey: ABLHZERWJZPBLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-methyl-1H-[1,6]naphthyridin-2-one 、 2-methyl-N-pyridin-4-yl-acrylamide 以to produce 1,2,3,4-tetrahydro-3-methyl-2-oxo-1,6-naphthyridine的产率得到3,4-dihydro-3-methyl-1,6-naphthyridin-2(1H)-one
  参考文献：
  名称：

  5-(Hydroxyalkyl or alkanoyloxymethyl)-1,6-naphthyridin-2(1H)-one and

  摘要：

  4-R'-5-Q-1,6-萘啶并[2(1H)-酮]（I），其中R'为氢或甲基，Q为羟甲基，1-羟乙基脂肪酰氧甲基或1-脂肪酰氧乙基，通过首先将4-R'-5-乙酰基（或正丙酰基）-6-[2-(二低烷基)氨基]-2(1H)-吡啶酮[III]与羟胺或其盐反应，生成4-R'-5-Q'-1,6-萘啶并[2(1H)-酮]-6-氧化物（II），其中R'如上所述，Q'为甲基或乙基；然后将II与脂肪酸酐反应，生成Q为脂肪酰氧甲基或1-脂肪酰氧乙基的I；然后水解所述的脂肪酰氧甲基或乙基化合物，生成Q为羟甲基或1-羟乙基的I。还显示了II和Q为羟甲基、1-羟乙基或脂肪酰氧甲基的I的强心作用。

  公开号：

  US04532247A1
• 作为产物：
  描述：

  甲基丙烯酰氯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 2-methyl-N-pyridin-4-yl-acrylamide
  参考文献：
  名称：

  WO2006/55184

  摘要：

  公开号：

文献信息

• A Poly(cobaloxime)/Carbon Nanotube Electrode: Freestanding Buckypaper with Polymer-Enhanced H₂ -Evolution Performance
  作者：Bertrand Reuillard、Julien Warnan、Jane J. Leung、David W. Wakerley、Erwin Reisner

  DOI：10.1002/anie.201511378

  日期：2016.3.14

  A freestanding H2‐evolution electrode consisting of a copolymer‐embedded cobaloxime integrated into a multiwall carbon nanotube matrix by π–π interactions is reported. This electrode is straightforward to assemble and displays high activity towards hydrogen evolution in near‐neutral pH solution under inert and aerobic conditions, with a cobalt‐based turnover number (TONCo) of up to 420. An analogous

  报道了一种独立式 H 2析出电极，该电极由通过 π-π 相互作用集成到多壁碳纳米管基质中的共聚物嵌入钴肟组成。该电极组装简单，在惰性和有氧条件下，在接近中性 pH 值的溶液中表现出高析氢活性，钴基周转数 (TON Co ) 高达 420。具有单体钴肟的类似电极显示出更少的析氢活性。 TON Co仅为 80 时的活性。这些结果表明，除了巴基纸多孔网络的高表面积之外，聚合物支架还为催化剂提供了稳定的环境，从而进一步提高了催化性能。因此，我们确定使用多功能共聚物结构是增强分子电催化剂性能的可行策略。
• Certain 2-(1H)-pyridinones cardiotonic compositions containing same and
  申请人：Sterling Drug Inc.

  公开号：US04415580A1

  公开（公告）日：1983-11-15

  1-R"-3-Q-4-R'-5-R-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is lower-alkyl, R' is hydrogen or methyl, R" is hydrogen or lower-alkyl, and Q is hydrogen, hydroxy, amino, cyano, carbamyl, carboxy or aminocarbamyl, are useful as cardiotonic agents (I, Q is hydrogen, hydroxy, amino, cyano or carbamyl) and/or intermediates therefor (I, Q is carboxy, aminocarbamyl, hydrogen, amino, cyano or carbamyl). Also shown are 3-Q"-4-R'-5-(RCO)-6-[2-(di-lower-alkylamino)ethenyl]-2(1H)-pyridinones (II) or salts thereof, where R and R' are as above and Q' is hydrogen or cyano, which are useful as cardiotonics (II, Q' is hydrogen) and/or intermediates (II, Q' is cyano or hydrogen). Processes for preparing the compounds of formulas I and II are shown.

  1-R"-3-Q-4-R'-5-R-1,6-萘啶并[2(1H)-酮]（I）或其盐，其中R为低碳基，R'为氢或甲基，R"为氢或低碳基，Q为氢、羟基、氨基、氰基、氨基甲酰基、羧基或氨基甲酰基，可作为心力衰竭药物（I，Q为氢、羟基、氨基、氰基或氨基甲酰基）和/或其中间体（I，Q为羧基、氨基甲酰基、氢、氨基、氰基或氨基甲酰基）。还显示了3-Q"-4-R'-5-(RCO)-6-[2-(二低碳基氨基)乙烯基]-2(1H)-吡啶酮（II）或其盐，其中R和R'如上所述，Q'为氢或氰基，可作为心力衰竭药物（II，Q'为氢）和/或其中间体（II，Q'为氰基或氢）。显示了制备I和II式化合物的过程。
• 5-Alkyl-1,6-naphthyridin-2(1H)-ones and cardiotonic use thereof
  申请人：Sterling Drug Inc.

  公开号：US04517190A1

  公开（公告）日：1985-05-14

  1-R"-3-Q-4-R'-5-R-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is lower-alkyl, R' is hydrogen or methyl, R" is hydrogen or lower-alkyl, and Q is hydrogen, hydroxy, amino, cyano, carbamyl, carboxy or aminocarbamyl, are useful as cardiotonic agents (I, Q is hydrogen, hydroxy, amino, cyano or carbamyl) and/or intermediates therefor (I, Q is carboxy, aminocarbamyl, hydrogen, amino, cyano or carbamyl). Also shown are 3-Q'-4-R'-5-(RCO)-6-[2-(di-lower-alkylamino)ethenyl]-2(1H)-pyridinones (II) or salts thereof, where R and R' are as above and Q' is hydrogen or cyano, which are useful as cardiotonics (II, Q' is hydrogen) and/or intermediates (II, Q' is cyano or hydrogen). Processes for preparing the compounds of formulas I and II are shown.

  1-R"-3-Q-4-R'-5-R-1,6-萘啶并[2(1H)-酮]（I）或其盐，其中R为低碳基，R'为氢或甲基，R"为氢或低碳基，Q为氢、羟基、氨基、氰基、氨基甲酰基、羧基或氨基甲酰基，作为强心剂（I，Q为氢、羟基、氨基、氰基或氨基甲酰基）和/或其中间体（I，Q为羧基、氨基甲酰基、氢、氨基、氰基或氨基甲酰基）有用。还显示了3-Q'-4-R'-5-(RCO)-6-[2-(二低碳基氨基)乙烯基]-2(1H)-吡啶酮（II）或其盐，其中R和R'如上所述，Q'为氢或氰基，它们作为强心剂（II，Q'为氢）和/或中间体（II，Q'为氰基或氢）有用。显示了制备公式I和II化合物的过程。
• 3-Substituted-5-alkyl-1,6-naphthyridin-2(1H)-ones, cardiotonic use and
  申请人：Sterling Drug Inc.

  公开号：US04559347A1

  公开（公告）日：1985-12-17

  1-R"-3-Q-4-R'-5-R-1,6-naphthyridin-2(1H)-ones (I) or salts thereof, where R is lower-alkyl, R' is hydrogen or methyl, R" is hydrogen or lower-alkyl, and Q is hydrogen, hydroxy, amino, cyano, carbamyl, carboxy or aminocarbamyl, are useful as cardiotonic agents (I, Q is hydrogen, hydroxy, amino, cyano or carbamyl) and/or intermediates therefor (I, Q is carboxy, aminocarbamyl, hydrogen, amino, cyano or carbamyl). Also shown are 3-Q'-4-R'-5-(RCO)-6-[2-di-lower-alkylamino)ethenyl]-2(1H)-pyridinones (II) or salts thereof, where R and R' are as above and Q' is hydrogen or cyano, which are useful as cardiotonics (II, Q' is hydrogen) and/or intermediates (II, Q' is cyano or hydrogen). Processes for preparing the compounds of formulas I and II are shown.

  1-R"-3-Q-4-R'-5-R-1,6-萘啶-2(1H)-酮(I)或其盐，其中R是低碳基，R'是氢或甲基，R"是氢或低碳基，Q是氢、羟基、氨基、氰基、氨基甲酰基、羧基或氨基甲酰基，可用作心力衰竭药物（I，Q为氢、羟基、氨基、氰基或氨基甲酰基）和/或其中间体（I，Q为羧基、氨基甲酰基、氢、氨基、氰基或氨基甲酰基）。还显示了3-Q'-4-R'-5-(RCO)-6-[2-二-低碳基氨基)乙烯基]-2(1H)-吡啶酮(II)或其盐，其中R和R'如上所述，Q'是氢或氰基，可用作心力衰竭药物（II，Q'为氢）和/或其中间体（II，Q'为氰基或氢）。显示了制备式I和式II化合物的方法。
• 5-(Hydroxyalkyl or alkanoyloxymethyl)-1,6-naphthyridin-2(1H)-one and
  申请人：Sterling Drug Inc.

  公开号：US04532247A1

  公开（公告）日：1985-07-30

  4-R'-5-Q-1,6-naphthyridin-2(1H)-ones (I), where R' is hydrogen or methyl and Q is hydroxymethyl, 1-hydroxyethyl alkanoyloxymethyl or 1-alkanoyloxyethyl, are produced by first reacting 4-R'-5-acetyl(or n-propanoyl)-6-[2-(di-lower-alkylamino]-2(1H)-pyridinone [III] with hydroxylamine or salt thereof to produce 4-R'-5-Q'-1,6-naphthyridin-2(1H)-one-6-oxide (II), where R' is defined as above and Q' is methyl or ethyl; next reacting II with an alkanoic anhydride to produce I where Q is alkanoyloxymethyl or 1-alkanoyloxyethyl; and, then hydrolyzing said alkanoyloxymethyl or -ethyl compound to produce I where Q is hydroxymethyl or 1-hydroxyethyl. Also shown is the cardiotonic use of II and I where Q is hydroxymethyl, 1-hydroxyethyl or alkanoyloxymethyl.

  4-R'-5-Q-1,6-萘啶并[2(1H)-酮]（I），其中R'为氢或甲基，Q为羟甲基，1-羟乙基脂肪酰氧甲基或1-脂肪酰氧乙基，通过首先将4-R'-5-乙酰基（或正丙酰基）-6-[2-(二低烷基)氨基]-2(1H)-吡啶酮[III]与羟胺或其盐反应，生成4-R'-5-Q'-1,6-萘啶并[2(1H)-酮]-6-氧化物（II），其中R'如上所述，Q'为甲基或乙基；然后将II与脂肪酸酐反应，生成Q为脂肪酰氧甲基或1-脂肪酰氧乙基的I；然后水解所述的脂肪酰氧甲基或乙基化合物，生成Q为羟甲基或1-羟乙基的I。还显示了II和Q为羟甲基、1-羟乙基或脂肪酰氧甲基的I的强心作用。